Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis

    Basic Details
    Date Posted
    Tuesday, June 14, 2022
    Status
    Complete
    Medical Product
    bamlanivimab
    bamlanivimab etesevimab
    casirivimab imdevimab
    Health Outcome(s)
    utilization
    Description

    In this report we estimated rates of monoclonal antibody (mAb) utilization, including bamlanivimab, casirivimab and/or imdevimab, and bamlanivimab and etesevimab, among authorized and unauthorized users, and examined counts of patients with Coronavirus Disease 2019 (COVID-19) in the Rapid COVID Sentinel Distributed Database (SDD).

    • Group 1: The study period includes data from November 1, 2020 to June 22, 2021. We distributed this request to three Sentinel Data Partners on August 2, 2021.
    • Group 2: The study period includes data from November 1, 2020 to June 30, 2021. We distributed this request to two Sentinel Data Partners on August 2, 2021.

     

    Additional Details
    FDA Center
    CDER
    Time Period
    November 1, 2020 - June 22, 2021; November 1, 2020 - June 30, 2021
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)